CompletedNot Applicable

Safety and Efficacy of Trastuzumab BS

Japan8 participantsStarted 2023-08-09

Plain-language summary

To confirm the safety and efficacy of this drug under the actual use

Who can participate

Age range0 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with unresectable advanced/recurrent gastric cancer who are confirmed to have HER2 overexpression and started treatment with this drug\* * Patients who receive this drug\* for the first time after this drug\* is launched \* Not including the biological product, HERCEPTIN, and biosimilars of HERCEPTIN other than this drug Exclusion Criteria: \- not specified in this study

What they're measuring

The Incidence of Adverse Drug Reactions (ADRs)

Timeframe: From Day 1 to 28 days after the last dose within 24 weeks; to the first dose after 24 weeks; or to the next treatment. If discontinued before 24 weeks, it was until 28 days after discontinuation or until the next treatment. Maximum duration was 28 weeks.

Trial details

NCT IDNCT04181333

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-03-27

Results submitted2026-02-17

View on ClinicalTrials.gov More Gastric Cancer trials